Open Access

Disrupting myddosome assembly in diffuse large B‑cell lymphoma cells using the MYD88 dimerization inhibitor ST2825

  • Authors:
    • Xin Wang
    • Yuan Tan
    • Zhenglan Huang
    • Ningshu Huang
    • Miao Gao
    • Fangzhu Zhou
    • Jing Hu
    • Wenli Feng
  • View Affiliations

  • Published online on: August 19, 2019     https://doi.org/10.3892/or.2019.7282
  • Pages: 1755-1766
  • Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Diffuse large B‑cell lymphoma (DLBCL), the most common type of non‑Hodgkin's lymphoma, is classified into germinal center and activated B cell (ABC) subtypes. The myeloid differentiation primary response gene 88 (MYD88) L265P mutation is the most prevalent oncogenic mutation among patients with ABC DLBCL, the subtype that has the more inferior outcome. MYD88 oligomerization driven by the L265P mutant augments myddosome assembly and triggers the activation of nuclear factor kappa‑light‑chain‑enhancer of activated B cells (NF‑κB) signaling, highlighting MYD88 oligomerization as a potential therapeutic target for this malignancy. The synthetic peptidomimetic compound ST2825, which has previously been used as an anti‑inflammatory agent, has been reported to inhibit MYD88 dimerization. In the present study, the anticancer effects of ST2825 were investigated using L265P‑expressing ABC DLBCL cell lines. Using confocal microscopy and high‑molecular‑weight fraction experiments, it was revealed that L265P‑associated myddosome assembly was disrupted by ST2825. The results also revealed that disrupting myddosome assembly promoted the death of ABC DLBCL cells harboring the L265P mutation, as well as downregulating survival signals, including the inhibition of NF‑κB and the suppression of IL‑10 and interferon‑β production. Further co‑immunoprecipitation studies demonstrated that MYD88 bound to BTK in L265P‑DLBCL cells, and that this binding was abrogated following ST2825 treatment. Furthermore, the combination of myddosome‑assembly disruption and BTK or BCL‑2 signaling inhibition led to synergistic ABC DLBCL cell death, and more robust inhibition of NF‑κB activity or increased apoptosis, respectively. The results of the present study provide evidence that the synthetic peptidomimetic compound ST2825, which targets myddosome assembly, may serve as a pharmacological inhibitor. ST2825 has the potential for clinical use in patients with L265P DLBCL, and other B‑cell neoplasms driven by activated MYD88 signaling.

Introduction

Diffuse large B-cell lymphoma (DLBCL) is an aggressive form of B-cell lymphoma, which is the most common type of non-Hodgkins lymphoma (NHL), and comprises ~30% of all NHL neoplasms. Over half of all DLBCLs are curable using standard chemotherapy (cyclophosphamide, doxorubicin, vincristine and prednisone) combined with rituximab (R-CHOP), while approximately one third of cases will relapse or become refractory following first line therapy (1,2). The two primary subtypes of DLBCL, termed germinal center B cell (GCB) and activated B cell (ABC) have been identified via gene expression profiling studies (3). The distinct genetic characteristics of these two subtypes suggest that they arise from different stages of lymphoid differentiation, with the GCB subtype deriving from the lymphoid cells residing in the germinal center, and the ABC subtype from B cells at a plasmablastic stage. This results in different clinical features and prognoses, where following R-CHOP combination treatment, the prognosis of patients with the ABC subtype is poorer than those with the GCB subtype, who possess a 3-year progression-free survival (PFS) rate of 40 vs. 75%, respectively (4). The pathogenic hallmark of ABC DLBCL is the constitutive activation of the NF-κB pathway, which is often caused by mutations occurring following the upstream activation of the B-cell receptor (BCR) and Toll-like receptors (TLR) pathways (5). These activating mutations were identified in subsets of patients with ABC DLBCL, and include mutations in CD79B, caspase recruitment domain-containing protein 11 (CARD11) in the BCR pathway (6,7) and myeloid differentiation primary response gene 88 (MYD88) in the TLR pathway (8).

The human TLRs, first reported in the 1990s, are functionally involved in both innate immunity and the initiation of adaptive immune responses (9). MYD88 is a key adaptor molecule for the majority of TLR and IL-1 receptor (IL-1R) signaling cascades. The MYD88 protein contains both a Toll/interleukin-1 receptor (TIR) domain that can bind to the TIR domain of TLRs, and a death domain (DD), which provides a docking site for IL-1R-associated kinases (IRAKs). It has been demonstrated that six MYD88 molecules, four IRAK4 and four IRAK1 or IRAK2 molecules are able to associate via their DDs to form a high-molecular-weight (HMW) (>180 kDa) complex, the myddosome. The myddosome platform is essential for the activation of the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathway via a cascade of phosphorylation events that originate from the phosphorylation of IRAK4, the most upstream kinase in this cascade (10,11). Highly recurrent somatic mutations in MYD88 were first demonstrated in ABC DLBCL by Ngo et al (8), with a specific point mutation (L265P) occurring most frequently; L265P was observed in ~29% of ABC DLBCL cases, but rarely in GCB DLBCL. The high prevalence of MYD88 L265P in patients with Waldenstrom macroglobulinemia (WM) has also been reported in previous publications, with an observed mutation frequency rate of 87% (observed in 1,324 of 1,520 patients with WM, from 25 publications) (12). In addition, MYD88 L265P has also been identified in other types of B-cell neoplasm, with mutation frequency rates in monoclonal gammopathy of undetermined significance of the IgM class (IgM MGUS; 52%), primary DLBCL of the central nervous system (CNS; 70%), cutaneous DLBCL of leg-type (54%) and testicular DLBCL (74%) (12). Consistent with previous studies, the majority of these subtypes of DLBCL are of ABC origin. Ngo et al (8) further demonstrated that MYD88 L265P was a gain-of-function driver mutation, which promoted ABC DLBCL cell survival by assembling a myddosome complex and the phosphorylation of IRAK kinases; this resulted in constitutive NF-κB activation, type I interferon (IFN) signaling and IL-6/IL-10-engaged autocrine activation of the JAK-STAT 3 pathway (8).

In ABC DLBCL cells, interactions between MYD88 L265P-mutated and wild-type (WT) TIR domains enhance MyD88 oligomerization, which serves a key role in myddosome complex formation, resulting in the recruitment of IRAKs and induced NF-κB signaling activation (13). ST2825, a synthetic peptidomimetic compound, interferes with the association between MYD88 proteins, potentially by targeting the interface between the TIR domains (14). Although MYD88 L265P is essential in promoting the survival of ABC DLBCL cells, the therapeutic strategies for targeting MYD88 remain largely undetermined. In the present study, the ability of ST2825 to disrupt MYD88 oligomerization-induced myddosome assembly was investigated in ABC DLBCL cells, in addition to the subsequent ability to inhibit NF-κB signaling and tumor cell survival.

Materials and methods

Reagents

ST2825 was purchased from MedChemExpress. The Bruton's tyrosine kinase (BTK) inhibitor ibrutinib, and B-cell lymphoma-2 (BCL-2) inhibitor ABT-199 were purchased from Selleck Chemicals. All drugs were dissolved in 100% dimethyl sulfoxide (DMSO). For all samples in all of the experiments, the final DMSO concentrations were diluted to 0.1% with cell culture media, including the vehicle controls.

Cell lines and cell culture

SU-DHL-4, OCI-LY10 and TMD8 cell lines were purchased from the Cell Bank of Type Culture Collection of the Chinese Academy of Sciences. The MYD88 L265P mutation of each cell line was identified using Sanger sequencing. The cells were cultured in RPMI-1640 supplemented with 10% fetal bovine serum (FBS; Gibco; Thermo Fisher Scientific, Inc.). The HEK293T cell line was cultured in Dulbecco's modified Eagle's medium (DMEM; Gibco; Thermo Fisher Scientific, Inc.) with 10% FBS. All cell lines were cultured at 37°C in a 5% CO2 incubator.

Evaluation of cell viability and apoptosis

Cell viability was assessed using WST-1 reagent (Roche Diagnostics) as instructed by the manufacturer. Briefly, ~2×104 cells/well were seeded into 96-well plates and treated with either the vehicle (DMSO) or ST2825 at serial concentrations for 24, 48 or 72 h. After treatment, 10 µl WST-1 reagent was added to each well, followed by a 4-h incubation at 37°C. Cell viability was calculated by measuring the absorbance at 440 nm using a 96-well plate reader, and the data were normalized to that of the vehicle-treated cells. For drug combination experiments, cell viability was determined 72 h after treatment with the indicated drugs. Flow cytometric analysis of apoptosis was performed using an Annexin V-FITC Apoptosis Detection kit (Sigma-Aldrich; Merck KGaA) 48 h after ST2825 treatment (5 or 10 µM) according to the manufacturer's protocol; the results were acquired using a flow cytometer (BD Influx; BD Biosciences) and analyzed using BD FACSuite software version 1.0.6. For drug combination experiments, the apoptotic cell populations were analyzed 48 h after treatment with the indicated drugs. The nuclear morphology of the apoptotic cells was further examined using DAPI staining. Cells were collected and coated onto slides after washing with PBS three times. The cells were then fixed in 4% paraformaldehyde at room temperature for 15 min and then permeabilized with 0.1% Triton X-100 at 37°C for 5 min. The cells were subsequently stained with 5 µg/ml DAPI in a dark room at 37°C for 15 min. After three washes with PBS, the cells were visualized using a fluorescence microscope (Eclipse 80i; Nikon Corporation) under a 40× oil immersion objective.

Western blot analysis

Western blot analysis was performed as previously described (15). Cells were lysed with RIPA lysis buffer supplemented with proteinase and phosphatase inhibitors (Cell Signaling Technology, Inc.) at 4°C for 20 min. The supernatants were collected after centrifugation at 13,000 × g for 15 min (4°C), and the protein concentration was determined using a bicinchoninic acid (BCA) protein assay kit (Thermo Fisher Scientific, Inc.). Equal amounts of protein extract (30 µg per lane) were loaded for separation onto a 10% SDS-PAGE gel and transferred to PVDF membranes (EMD Millipore), before blocking in 5% non-fat milk/TBST at room temperature for 1 h. Then, the membranes were incubated overnight at 4°C with primary antibodies (all purchased from Cell Signaling Technology, Inc., and used at a dilution of 1:1,000) against MYD88 (cat. no. 4823S), BTK (cat. no. 8547S), phospho-BTK (cat. no. 5082S), inhibitor of NF-κB (IκB; cat. no. 4812S) and phospho-IκB (cat. no. 2859S), followed by incubation with anti-rabbit horseradish peroxidase (HRP)-conjugated secondary antibody (cat. no. sc-2030; Santa Cruz Biotechnology, Inc.; 1:5,000) for 1 h at room temperature. The β-actin antibody (cat. no. ab8227; Abcam) was used at a 1:1,000 dilution. Detection was performed using an enhanced chemiluminescence substrate (ECL; EMD Millipore), and the signals were visualized and analyzed using the Bio-Rad Gel Imaging System and the Cool Imager™ workstation II (Viagene, Biotech, Inc.).

MyD88 protein aggregation in DLBCL cell lines (OCI-LY10 and TMD8) was analyzed using fractionated cell lysates. Following overnight treatment with DMSO or 10 µM ST2825, 5×106 cells were incubated in each well of a 6-well plate and then collected and lysed using cell lysis buffer (Beyotime Institute of Biotechnology) supplemented with PMSF and Benzonase (Sigma-Aldrich; Merck KGaA). The protein concentration was determined using a BCA protein assay kit (Thermo Fisher Scientific, Inc.) and equal amounts of cell lysates (60 µg) were then fractionated by centrifugation (16,000 × g, 10 min); the supernatant fractions were regarded as whole cell lysates (WCL) and the pellet fractions as insoluble HMW aggregates. The pellets were then washed with PBS and dissolved by boiling in SDS sample buffer with shaking. Western blotting was conducted using the aforementioned anti-MYD88 (Cell Signaling Technology, Inc.) and anti-β-actin (Abcam) antibodies and goat anti-rabbit HRP-conjugated secondary antibody at the indicated dilutions.

Co-immunoprecipitation

Cells from each line were lysed using cell lysis buffer for western and immunoprecipitation (Beyotime Institute of Biotechnology) supplemented with 1 mM PMSF. The samples were centrifuged at 13,000 × g for 15 min, and the protein concentration was determined using a BCA protein assay kit (Thermo Fisher Scientific, Inc.). Then protein A/G coated magnetic beads (Bio-Rad Laboratories, Inc.) were incubated with 5 µg IP antibodies against MYD88 or BTK (Cell Signaling Technology, Inc.) at room temperature with rotation for 10 min. After washing with PBS-T, the antibody-conjugated beads were added into the antigen-containing lysate, and rotated for 1 h at room temperature. Immunoprecipitates were then washed three times with PBS-T, separated on a magnetic stand and eluted using Laemmli loading buffer for further immunoblotting analysis.

Confocal microscopy

HEK293T cells were seeded into 12-well plates (2×105 cells/well) 24 h before transfection to achieve a confluency of 50–70%. Cells were then transiently transfected with 2 µg mCitrine-TIR WT or mCitrine-TIR L265P plasmids using Lipofectamine™ 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol. After 24 h, the cells were treated with DMSO or 10 µM ST2825 and incubated for a further 48 h. Following incubation, the cells were observed using a laser scanning Nikon A1R confocal microscope under a 40× oil immersion objective (numerical aperture, 1.4). An excitation of 488 and 520–570 nm emission were used for visualization. The plasmids for mCitrine-TIR WT or L265P mutant were provided by Dr Roman Jerala (13).

NF-κB reporter assays

CMV-Renilla luciferase lentivirus (Cignal Lenti CMV Renilla Control; Qiagen, Inc.) was used as an internal control for normalization, and NF-κB reporter lentivirus with firefly luciferase expression (Cignal Lenti NF-κB Reporter; Qiagen, Inc.) was used as the experimental reporter. The two lentiviruses were used to co-transfect the OCI-LY10 and TMD8 cells. Briefly, OCI-LY10 and TMD8 cells were resuspended in 0.5 ml lentivirus-containing medium (containing 250 µl Cignal Lenti NF-κB Reporter and 250 µl Cignal Lenti CMV Renilla Control) at a concentration of 1×106 cells/ml in a 24-well tissue culture plate in the presence of polybrene (8 µg/ml). The plates were centrifuged at 800 × g for 90 min at 32°C. The cells were then washed and resuspended in fresh medium for an additional 72 h. Then puromycin and hygromycin were used together for selection. For the drug experiments, cells were subsequently seeded at a density of 4×105 cells/ml and treated for 12 h with the vehicle, ST2825, ibrutinib or a combination of ST2825 and ibrutinib at the indicated concentrations. Luciferase activity was measured in 96-well plates using the Dual-Luciferase Reporter Assay system (Promega Corporation) according to the manufacturer's protocol.

Cytokine measurement

The two ABC DLBCL cell lines were cultured in fresh media and treated for 24 h with 5 or 20 µM ST2825 or DMSO. The concentrations of IL-10 and IFN-β in the culture supernatants were measured by ELISA (cat. no. DY217B-05 and DY814-05, respectively; R&D Systems, Inc.) according to the manufacturer's protocol. All experiments were performed in triplicate.

Synergism analysis

Synergism of the drug combinations (including ST2825 combined with ibrutinib or ABT-199) was evaluated using CalcuSyn software (Premier Biosoft International), which is based on the median-effect principle applied by Chou and Talalay (16). The combined effects and combination index (CI) for each dose combination were calculated and are presented as a heat map. Drug synergism, addition and antagonism were defined by CI values of <1.0, 1.0 and >1.0, respectively.

Statistical analysis

Statistical analysis of the experimental data was performed using GraphPad Prism software version 6 (GraphPad Software, Inc.), and the data are presented as the mean ± standard deviation, unless otherwise indicated. The unpaired t-test was used to assess the statistical significance of the differences between two groups, and one-way analysis of variance with Dunnett's or Tukey's test was used for those between multiple groups. P<0.05 was considered to indicate a statistically significant difference.

Results

MYD88 oligomerization augmented via the L265P-mutated TIR domain is blocked by ST2825

To determine whether oligomerization of the MyD88 TIR-L265P mutants could be blocked by ST2825, MyD88 TIR WT or mutant linked to the fluorescent protein mCitrine were expressed in HEK293T cells. Consistent with the results of a previous report (13), mCitrine-TIR mutants were strongly aggregated, whilst this was not the case for the WT mCitrine TIR. Furthermore, the aggregation of mCitrine-TIR mutants was markedly inhibited following treatment with ST2825 (Fig. 1A).

The HMW fraction was separated from the cellular lysates via centrifugation, and western blotting was used to determine the presence of MyD88 aggregates in the pelleted HMW fractions. MyD88 aggregation was detected in the HMW fraction in DLBCL cell lines with the L265P mutation (OCI-LY10 and TMD8). The changes in MyD88 aggregation following treatment with ST2825 were then investigated by comparing the ratios of endogenous MyD88 levels between pelleted HMW fractions and whole cell lysates. Fig. 1B and C illustrate a significantly lower pellet:lysate ratio in the ST2825-treated cells compared with the DMSO treated cells, thus indicating that the degree of MyD88 aggregation was significantly decreased following ST2825 treatment. A previous study indicated that the formation of MYD88-mutant-containing aggregates coincided with that of myddosome complexes (13). According to these data, it may be that augmented MyD88 oligomerization is blocked by ST2825 in ABC DLBCL cells, resulting in the disruption of myddosome assembly.

Disruption of myddosome assembly inhibits cell survival and promotes apoptosis in ABC DLBCL cells with the L265P mutation

WST-1 assays were used to evaluate the impact of ST2825-induced myddosome assembly disruption on tumor cell survival. As presented in Fig. 2, ST2825 exerted greater cytotoxicity on MYD88-mutated (OCI-LY10 and TMD8) vs. WT (SU-DHL-4) B-cells. Compared with the DMSO control groups, the cell viability of OCI-LY10 cells treated with ST2825 for 72 h was decreased in a concentration-dependent manner, with ~50% inhibition at 5 µM ST2825, ~60% at 10 µM and ~70% at 20 µM (P<0.01; Fig. 2A). Similar results were observed in TMD8 cells (P<0.01; Fig. 2B). However, the growth inhibition effects of ST2825 on SU-DHL-4 cells were only ~20-25% at 10 or 20 µM after 72 h of treatment, though these results were still significant. Flow cytometry revealed that the percentage of apoptotic cells (including early and late apoptotic cells) was significantly increased in OCI-LY10 and TMD8 cells 48 h after treatment with ST2825 (P<0.01; Figs. 2D and S1), while no significant difference was observed in SU-DHL-4 cells. Consistent with these results, the characteristic apoptotic morphological changes (condensed and fragmented nuclear) were observed by DAPI staining in OCI-LY10 and TMD8 cells treated with ST2825, while there were no obvious morphological changes in SU-DHL-4 cells (Fig. 2E).

Activated MYD88 signaling pathway driven by the L265P mutation is inhibited by ST2825

Since the disruption of myddosome assembly inhibited survival and induced apoptosis in MYD88-L265P DLBCL cells, the present study investigated the underlying molecular mechanism responsible for this effect. Gain-of-function driver mutation L265P engages the NF-κB pathway by facilitating the phosphorylation and degradation of IκB proteins (8). Treatment of ABC DLBCL cell lines with ST2825 resulted in decreased ratios of phosho-/total IκB in both OCI-LY10 and TMD8 cells (Fig. 3A). To further investigate NF-κB activity, NF-κB reporter assays were performed. ST2825 decreased transcription of the NF-κB-dependent luciferase reporter in OCI-LY10 and TMD8 cells (Fig. 3B). In addition to the NF-κB pathway, JAK-STAT3 signaling was also demonstrated to contribute to cell survival in ABC DLBCL. MYD88 L265P mutations promote JAK-STAT3 signaling via the increased production of IL-6 and IL-10 in ABC DLBCL tumors. Furthermore, the activation of MYD88 signaling in MYD88-L265P DLBCL cells can induce IFN-β production, which may be involved in the immune modulation of the ABC DLBCL cell microenvironment (8). The present study demonstrated that treatment with ST2825 significantly reduced the secretion of IL-10 and IFN-β (Fig. 3C and D), while such inhibition was not observed for IL-6 secretion (data not shown).

BTK is associated with MYD88, which is altered following treatment with ST2825 in MYD88 L265P-expressing ABC DLBCL cells

Chronically active BCR signaling, responsible for the constitutive activation of the NF-κB pathway, is important for cell survival in ABC DLBCL. The BCR signaling component BTK serves a key role in triggering NF-κB activation in the majority of ABC DLBCLs (6,17). According to the sequencing results of 155 ABC DLBCL biopsy samples, Ngo et al (8) identified that the most common mutations were found in MYD88, CD79B/A, A20 and CARD11. These mutations partially overlapped, and the overlap between the MYD88 L265P and CD79B/A mutations had the highest frequency. Among cases with a MYD88 L265P mutation, 34% had a simultaneous CD79B/A mutation, which was reversed among cases with a CD79B/A mutation; even more had a simultaneous MYD88 L265P mutation (43%). These data indicate that there may be crosstalk between chronically-active BCR and MYD88 signaling (8). In a previous study, co-immunoprecipitation experiments revealed that in HEK293 cells, ectopically expressed BTK associated with MYD88 (18). In addition, it was also reported that BTK interacted with MYD88 in lipopolysaccharide-stimulated macrophages to promote the activation of MYD88-dependent pathways (19). In the present study, co-immunoprecipitation experiments where performed to investigate whether endogenous MYD88 interacts with BTK in ABC DLBCL cells, with activation of the MYD88 signaling pathway driven by the L265P mutation. Robust MYD88 co-immunoprecipitation with BTK was observed in L265P-expressing ABC DLBCL cells (OCI-LY10 and TMD8) (Fig. 4A). This binding between BTK and MYD88 was also confirmed through reverse pull-down studies (Fig. 4B). It was further demonstrated that the binding of BTK with MYD88 was inhibited following treatment with ST2825 in OCI-LY10 and TMD8 cells (Fig. 4C). In addition, treatment with ST2825 decreased the ratio of phos-/total BTK expression in OCI-LY10 and TMD8 ABC DLBCL cell lines (Fig. 3A).

Disruption of myddosome assembly synergizes with BTK inhibition to enhance ABC DLBCL cell death

MYD88 and BCR signaling often converge at IκB, leading to constitutive activation of the NF-κB pathway in ABC DLBCL cells. In addition, a recent study demonstrated that MYD88, the BCR and TLR9 form a multi-protein supercomplex, which drives pro-survival-associated NF-κB signaling in ibrutinib-responsive DLBCL cells (20). Furthermore, the present study identified the direct interaction between BTK and MYD88 in ABC DLBCL cell lines. Thus, the potential dual inhibition of MYD88 and BTK signaling and its synergistic effects on ABC DLBCL cell death were investigated. The combination of ST2825 and the BTK inhibitor ibrutinib promoted OCI-LY10 and TMD8 cell death (Figs. 5A and B, S2A and B). The inhibitory effect for each combination at different doses was visualized using a heat map. Analysis of the CI indicated that ST2825 and ibrutinib were synergistic at most doses, though greater synergistic effects were observed at higher doses of ST2825 (≥1.3 µM) for both OCI-LY10 and TMD8 cells (Figs. 5C and S2C). The enhanced cytotoxicity was associated with stronger inhibition of NF-κB activity in tumor cells treated by dual inhibition, compared with that of each drug alone (Figs. 5D and S2D).

Disruption of myddosome assembly synergizes with BCL-2 inhibition to enhance ABC DLBCL cell death

BCL-2 upregulation is prevalent in B-cell lymphoma and promotes tumor cell survival by blocking apoptosis (21,22). In addition, high BCL-2 expression levels were associated with poor clinical outcome in patients with ABC DLBCL (23). Given that BCL-2 serves a key role in the underlying oncogenic mechanism of B-cell lymphoma, BCL-2-targeted therapy has developed rapidly in recent years (24). In the present study, combination treatment with ST2825 and the BCL-2 inhibitor ABT-199 enhanced OCI-LY10 and TMD8 cell death (Figs. 6A and B, S3A and B). Analysis of the CI indicated that ST2825 and ibrutinib were synergistic at higher doses of ST2825 (≥1.3 µM) and ABT-199 (≥0.5 µM) in OCI-LY10 cells (Fig. 5C). Similar results were revealed in TMD8 cells (Fig. S3C). This combination treatment also consistently promoted apoptosis, as indicated by the increased number of apoptotic cells (including early and late apoptotic cells) detected by flow cytometry, compared with treatment with the individual drugs alone (Figs. 6D, S3D and S4).

Discussion

Recurrent MYD88 L265P mutations have been demonstrated in numerous types of B-cell neoplasm, including IgM MGUS, WM, DLBCL, mucosa-associated lymphoid tissue lymphoma and chronic lymphocytic leukemia (12). MYD88 L265P has been demonstrated to be the most frequently occurring mutation in the ABC subtype of DLBCL (20–40%), whereas it is rarely observed in the GCB subtype (8,17,25,26). A study in Spain reported that the MYD88 L265P mutation was significantly associated with inferior PFS and overall survival in patients with DLBCL (P<0.01), and was identified as a significant risk factor for mortality (hazard ratio, 2.4) via multivariate Cox regression analysis (27). More recently, two studies identified four or five subtypes of DLBCL based on distinct genetic features and pathogenetic mechanisms, via comprehensive genetic analyses. The results of both studies demonstrated that the subtype associated with more frequent mutations in MYD88 indicated a less favorable patient outcome (25,26).

MYD88 L265P was identified as an oncogenic driver mutation, with enhanced phosphorylation of IRAK kinases and activation of the NF-κB and JAK-STAT3 signaling pathways, resulting in the promotion of cell survival in numerous B-cell neoplasms, including ABC DLBCL (8,12,28). Furthermore, mice occasionally developed ABC-DLBCL-like clonal lymphomas following conditional expression of MYD88 L265P in B cells specifically (29,30). MYD88 is a central adaptor to the TLRs/ IL-1R signaling pathway, which contains three distinct domains: A C-terminal TIR domain, an N-terminal DD and a short linker region in-between (31). During normal immune responses, TLRs are primarily stimulated by foreign ligands such as the chemical components of infecting microbes. Following ligand binding, MYD88 is recruited to the activated receptor, resulting in heterodimerization with the receptor and homodimerization with another MyD88 molecule via TIR-TIR interactions (32,33). These MYD88 oligomers further recruit the IRAKs via DDs, promoting myddosome formation and triggering subsequent downstream NF-κB and JAK-STAT3 signaling. The MYD88 L265P mutation, located in the TIR domain, reinforces dimerization between the mutant and WT TIR domains and augments MYD88 oligomerization. In contrast to native MYD88 oligomers, those containing L265P mutants can trigger myddosome assembly and constitutive activation of NF-κB signaling in the absence of external stimuli (13,34). The disruptive power of the proline residue potentially contributes to augmented oligomerization of MYD88 mutant TIR domains. The leucine-to-proline substitution at position 265 in the β-sheets (at the hydrophobic core of MYD88) would disrupt the secondary structure of the TIR domain, thus stabilizing the core of the TIR domain dimer interface (12,35). The BB-loop, interacting with the αE-helix, is critical for MYD88 TIR-TIR interactions (35,36). ST2825, a synthetic peptidomimetic that interacts with the BB-loop, competently inhibits MYD88 WT TIR-TIR interactions (14). Furthermore, it was observed that ST2825 was able to disrupt the aggregation of MYD88 mutant TIR domains in the present study, thus resulting in decreased cell viability and increased apoptosis of MYD88 L265P-expressing ABC DLBCL cells.

The NF-κB transcription factor family (which can be activated by the MYD88 L265P mutation) serves a crucial role in ABC DLBCL cell survival (8,37). IκBα has been regarded as a critical component of the NF-κB signaling pathway. The present study demonstrated that IκBα phosphorylation was blocked by inhibiting MYD88 oligomerization in L265P-expressing ABC DLBCL cells treated with ST2825. Consistent with these results, decreased NF-κB activity was observed following ST2825 treatment using a luciferase NF-κB reporter assay. Furthermore, the present study also revealed that ST2825 decreased the secretion of IL-10 and IFN-β (the production of which are mediated by MYD88), which may be involved in the immune modulation of the ABC DLBCL microenvironment (8).

BTK, a mediator from BCR activity to NF-κB, serves an essential role in chronically-active BCR signaling, which supports tumor cell survival in ABC DLBCL cells (6,17). As reported by Yang et al (38), it was also observed that MYD88 interacted with BTK in L265P ABC DLBCL cell lines, and that the binding between MYD88 and BTK was abrogated by ST2825. Furthermore, the present study demonstrated that the use of ST2825 inhibited BTK activity in MYD88 L265P-expressing ABC DLBCL cell lines. Collectively, the present study demonstrated that when bound to BTK, MYD88 L265P could influence the activity of the former. Given the association between MYD88 and BTK, and their critical oncogenic roles in L265P-expressing ABC DLBCL cells, the present study investigated the effects of the dual inhibition of MYD88 and BTK. The data revealed that the combined use of ST2825 and ibrutinib resulted in synergistic killing effects, which were associated with enhanced inhibition of NF-κB activity.

Based on the pathways regulated by MYD88 L265P activity, there are several therapeutic strategies that have been designed to halt this specific oncogenic process. The targets of these therapies include BTK, IRAK1/4, JAK and myddosome assembly. The BTK inhibitor ibrutinib, the only U.S. Food and Drug Administration approved drug capable of influencing the L265P driven pathway (potentially by abrogating the MYD88-BTK complex), inhibits the survival of L265P-expressing cell lines, which is consistent with the observations of the present study. A phase 1/2 clinical trial demonstrated that ibrutinib produced total responses in 37% of 38 patients with ABC DLBCL (17). The patients with concurrent MYD88 and BCR component mutations appeared to be more sensitive to ibrutinib, while those with MYD88 mutations independent of chronically-active BCR signaling exhibited resistance to ibrutinib. This indicates that novel drugs that are more specific to MYD88 signaling require further investigation. A number of IRAK inhibitors have demonstrated convincing abilities to inhibit the growth of L265P-expressing cell lines in pre-clinical models (3941). However, MYD88 dimerization may present a more favorable target considering its proximity to the origin of hyperactivity, particularly as IRAKs are not involved in all MyD88-dependent signaling. Mini-peptides that have been designed to compete with MYD88 TIR domain interactions disrupted myddosome signaling and blocked WM cell proliferation (42,43). Notably, ST2825 is a synthetic compound, created to mimic a portion in the BB-loop of the MYD88 TIR domain, which can inhibit MYD88 dimerization (14). In the present study, the use of ST2825 disrupted myddosome assembly and contributed to growth inhibition, as well as attenuating NF-κB activity in L265P ABC DLBCL cell lines.

The MYD88 L265P mutation frequently occurs alongside other genetic events in ABC-DLBCLs, such as CD79B mutations (4446), loss of the tumor suppressor TNFAIP3 or the overexpression of BCL-2 (30,34). It has also been revealed that to induce lymphoma formation, MYD88 L265P may need to occur in addition to other genetic alterations, while MYD88 mutations alone are potentially not sufficient. It has been reported that MYD88 L265P and CD79B mutations cooperate to block peripheral deletions and promote spontaneous plasmablast differentiation in B cells (46). In addition, TNFAIP3 loss enhances NF-κB signaling driven by MYD88 L265P, and contributes to ibrutinib resistance in lymphoma cell lines. Furthermore, MYD88 mutations cooperate with BCL-2 overexpression to promote self-reactive B cell accumulation and lymphomagenesis in vivo (30,34). These findings provide a framework for the rational design of combination therapy with dual inhibitors, targeting multiple signaling pathways. The present study demonstrated that the dual inhibition of MYD88 oligomerization (ST2825) and BTK activity (ibrutinib) results in synergistic cell death by decreasing NF-κB activity. It was also observed that combined treatment targeting both the myddosome (ST2825) and BCL-2 (ABT-199) lead to synergistic toxicity and increased apoptosis in ABC DLBCL cell lines.

To the best of our knowledge, the present study is the first to report that myddosome assembly is disrupted by the synthetic small-molecule compound ST2825 in MYD88 L265P ABC DLBCL cells, resulting in proliferation inhibition, increased apoptosis and decreased NF-κB activity. The interplay between the MYD88 mutant and BTK further confirms that oncogenic MYD88 L265P cooperates with BCR signaling to promote tumor cell survival. It was subsequently revealed that combined ST2825, either with the BTK inhibitor ibrutinib, or the BCL-2 inhibitor ABT-199, resulted in synergistic cell death in ABC DLBCL cells. Therefore, targeting myddosome assembly may be a promising therapeutic strategy for MYD88-mutated ABC DLBCL. Future studies may focus on developing more ST2825-like synthetic peptidomimetic compounds with improved efficacy and safety.

Supplementary Material

Supporting Data

Acknowledgements

The authors would like to thank Roman Jerala and Mateja M. Keber for supplying the plasmids and for their helpful discussion.

Funding

The present work was supported by the Chongqing Research Program of Basic Research and Frontier Technology (grant no. cstc2017jcyjA0632), Chongqing Health and Family Planning Commission Grant (grant no. zy201402109) to XW, and the Science and Technology Research Program of Chongqing Municipal Education Commission (grant no. KJ1600225) to Jing Hu.

Availability of data and materials

All data generated or analyzed during the present study are included in this published article (and its Supplementary files).

Authors' contributions

XW designed the research studies, performed the experiments, analyzed the data and wrote the manuscript. YT and NSH performed the experiments. JH and FZZ analyzed data and critically revised the manuscript. ZLH and MG collected and analyzed the data. WLF supervised the experimental work and critically revised the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Glossary

Abbreviations

Abbreviations:

DLBCL

diffuse large B-cell lymphoma

NHL

non-Hodgkins lymphoma

GCB

germinal center B cell

ABC

activated B cell

PFS

progression-free survival

BCR

B-cell receptor

TLR

toll-like receptors

CARD11

caspase recruitment domain-containing protein 11

NF-κB

nuclear factor-kappa B

MYD88

myeloid differentiation primary response gene 88

IL-1R

interleukin-1 receptor

TIR

Toll/interleukin-1 receptor

DD

death domain

HMW

high-molecular-weight

WM

Waldenstrom macroglobulinemia

WT

wild-type

BTK

Bruton's tyrosine kinase

BCL-2

B-cell lymphoma-2

IκB

inhibitor of NF-κB

CI

Combination index

References

1 

Teras LR, DeSantis CE, Cerhan JR, Morton LM, Jemal A and Flowers CR: 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin. 66:443–459. 2016. View Article : Google Scholar : PubMed/NCBI

2 

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI

3 

Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, et al: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 403:503–511. 2000. View Article : Google Scholar : PubMed/NCBI

4 

Pfreundschuh M, Kuhnt E, Trümper L, Osterborg A, Trneny M, Shepherd L, Gill DS, Walewski J, Pettengell R, Jaeger U, et al: CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol. 12:1013–1022. 2011. View Article : Google Scholar : PubMed/NCBI

5 

Rawlings DJ, Schwartz MA, Jackson SW and Meyer-Bahlburg A: Integration of B cell responses through Toll-like receptors and antigen receptors. Nat Rev Immunol. 12:282–294. 2012. View Article : Google Scholar : PubMed/NCBI

6 

Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB, Kohlhammer H, Lamy L, Zhao H, Yang Y, et al: Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature. 463:88–92. 2010. View Article : Google Scholar : PubMed/NCBI

7 

Lenz G, Davis RE, Ngo VN, Lam L, George TC, Wright GW, Dave SS, Zhao H, Xu W, Rosenwald A, et al: Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science. 319:1676–1679. 2008. View Article : Google Scholar : PubMed/NCBI

8 

Ngo VN, Young RM, Schmitz R, Jhavar S, Xiao W, Lim KH, Kohlhammer H, Xu W, Yang Y, Zhao H, et al: Oncogenically active MYD88 mutations in human lymphoma. Nature. 470:115–119. 2011. View Article : Google Scholar : PubMed/NCBI

9 

Medzhitov R, Preston-Hurlburt P and Janeway CA Jr: A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature. 388:394–397. 1997. View Article : Google Scholar : PubMed/NCBI

10 

Ntoufa S, Vilia MG, Stamatopoulos K, Ghia P and Muzio M: Toll-like receptors signaling: A complex network for NF-κB activation in B-cell lymphoid malignancies. Semin Cancer Biol. 39:15–25. 2016. View Article : Google Scholar : PubMed/NCBI

11 

Lin SC, Lo YC and Wu H: Helical assembly in the MyD88-IRAK4-IRAK2 complex in TLR/IL-1R signalling. Nature. 465:885–890. 2010. View Article : Google Scholar : PubMed/NCBI

12 

Yu X, Li W, Deng Q, Li L, His ED, Young KH, Zhang M and Li Y: MYD88 L265P mutation in lymphoid malignancies. Cancer Res. 78:2457–2462. 2018. View Article : Google Scholar : PubMed/NCBI

13 

Avbelj M, Wolz OO, Fekonja O, Benčina M, Repič M, Mavri J, Krüger J, Schärfe C, Delmiro Garcia M, Panter G, et al: Activation of lymphoma-associated MyD88 mutations via allostery-induced TIR-domain oligomerization. Blood. 124:3896–3904. 2014. View Article : Google Scholar : PubMed/NCBI

14 

Loiarro M, Capolunghi F, Fantò N, Gallo G, Campo S, Arseni B, Carsetti R, Carminati P, De Santis R, Ruggiero V and Sette C: Pivotal advance: Inhibition of MyD88 dimerization and recruitment of IRAK1 and IRAK4 by a novel peptidomimetic compound. J Leukoc Biol. 82:801–810. 2007. View Article : Google Scholar : PubMed/NCBI

15 

Li H, Huang Z, Gao M, Huang N, Luo Z, Shen H, Wang X, Wang T, Hu J and Feng W: Inhibition of YAP suppresses CML cell proliferation and enhances efficacy of imatinib in vitro and in vivo. J Exp Clin Cancer Res. 35:1342016. View Article : Google Scholar : PubMed/NCBI

16 

Chou TC: Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 70:440–446. 2010. View Article : Google Scholar : PubMed/NCBI

17 

Wilson WH, Young RM, Schmitz R, Yang Y, Pittaluga S, Wright G, Lih CJ, Williams PM, Shaffer AL, Gerecitano J, et al: Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 21:922–926. 2015. View Article : Google Scholar : PubMed/NCBI

18 

Jefferies CA, Doyle S, Brunner C, Dunne A, Brint E, Wietek C, Walch E, Wirth T and O'Neill LA: Bruton's tyrosine kinase is a Toll/interleukin-1 receptor domain-binding protein that participates in nuclear factor kappaB activation by Toll-like receptor 4. J Biol Chem. 278:26258–26264. 2003. View Article : Google Scholar : PubMed/NCBI

19 

Liu X, Zhan Z, Li D, Xu L, Ma F, Zhang P, Yao H and Cao X: Intracellular MHC class II molecules promote TLR-triggered innate immune responses by maintaining activation of the kinase Btk. Nat Immunol. 12:416–424. 2011. View Article : Google Scholar : PubMed/NCBI

20 

Phelan JD, Young RM, Webster DE, Roulland S, Wright GW, Kasbekar M, Shaffer AL III, Ceribelli M, Wang JQ, Schmitz R, et al: A multiprotein supercomplex controlling oncogenic signalling in lymphoma. Nature. 560:387–391. 2018. View Article : Google Scholar : PubMed/NCBI

21 

Cory S and Adams JM: The Bcl2 family: Regulators of the cellular life-or-death switch. Nat Rev Cancer. 2:647–656. 2002. View Article : Google Scholar : PubMed/NCBI

22 

Lenz G, Wright GW, Emre NC, Kohlhammer H, Dave SS, Davis RE, Carty S, Lam LT, Shaffer AL, Xiao W, et al: Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci USA. 105:13520–13525. 2008. View Article : Google Scholar : PubMed/NCBI

23 

Iqbal J, Neppalli VT, Wright G, Dave BJ, Horsman DE, Rosenwald A, Lynch J, Hans CP, Weisenburger DD, Greiner TC, et al: BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma. J Clin Oncol. 24:961–968. 2006. View Article : Google Scholar : PubMed/NCBI

24 

Davids MS: Targeting BCL-2 in B-cell lymphomas. Blood. 130:1081–1088. 2017. View Article : Google Scholar : PubMed/NCBI

25 

Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, Lawrence MS, Roemer MGM, Li AJ, Ziepert M, et al: Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 24:679–690. 2018. View Article : Google Scholar : PubMed/NCBI

26 

Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, Roulland S, Kasbekar M, Young RM, Shaffer AL, et al: Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med. 378:1396–1407. 2018. View Article : Google Scholar : PubMed/NCBI

27 

Fernández-Rodríguez C, Bellosillo B, García-García M, Sánchez-González B, Gimeno E, Vela MC, Serrano S, Besses C and Salar A: MYD88 (L265P) mutation is an independent prognostic factor for outcome in patients with diffuse large B-cell lymphoma. Leukemia. 28:2104–2106. 2014. View Article : Google Scholar : PubMed/NCBI

28 

Weber ANR, Cardona Gloria Y, Çınar Ö, Reinhardt HC, Pezzutto A and Wolz OO: Oncogenic MYD88 mutations in lymphoma: Novel insights and therapeutic possibilities. Cancer Immunol Immunother. 67:1797–1807. 2018. View Article : Google Scholar : PubMed/NCBI

29 

Janz S: Mouse model of MYD88L265P-dependent DLBCL. Blood. 127:2660–2661. 2016. View Article : Google Scholar : PubMed/NCBI

30 

Knittel G, Liedgens P, Korovkina D, Seeger JM, Al-Baldawi Y, Al-Maarri M, Fritz C, Vlantis K, Bezhanova S, Scheel AH, et al: B-cell-specific conditional expression of Myd88p.L252P leads to the development of diffuse large B-cell lymphoma in mice. Blood. 127:2732–2741. 2016. View Article : Google Scholar : PubMed/NCBI

31 

Hardiman G, Rock FL, Balasubramanian S, Kastelein RA and Bazan JF: Molecular characterization and modular analysis of human MyD88. Oncogene. 13:2467–2475. 1996.PubMed/NCBI

32 

Fekonja O, Benčina M and Jerala R: Toll/interleukin-1 receptor domain dimers as the platform for activation and enhanced inhibition of Toll-like receptor signaling. J Biol Chem. 287:30993–31002. 2012. View Article : Google Scholar : PubMed/NCBI

33 

Jing X, Tian Z, Gao P, Xiao H, Qi X, Yu Y, Ding X, Yang L and Zong L: HBsAg/β2GPI activates the NF-κB pathway via the TLR4/MyD88/IkBα axis in hepatocellular carcinoma. Oncol Rep. 40:1035–1045. 2018.PubMed/NCBI

34 

Wang JQ, Jeelall YS, Beutler B, Horikawa K and Goodnow CC: Consequences of the recurrent MYD88(L265P) somatic mutation for B cell tolerance. J Exp Med. 211:413–426. 2014. View Article : Google Scholar : PubMed/NCBI

35 

Vyncke L, Bovijn C, Pauwels E, Van Acker T, Ruyssinck E, Burg E, Tavernier J and Peelman F: Reconstructing the TIR side of the myddosome: A paradigm for TIR-TIR interactions. Structure. 24:437–447. 2016. View Article : Google Scholar : PubMed/NCBI

36 

Ohnishi H, Tochio H, Kato Z, Orii KE, Li A, Kimura T, Hiroaki H, Kondo N and Shirakawa M: Structural basis for the multiple interactions of the MyD88 TIR domain in TLR4 signaling. Proc Natl Acad Sci USA. 106:10260–10265. 2009. View Article : Google Scholar : PubMed/NCBI

37 

Pasqualucci L and Zhang B: Genetic drivers of NF-κB deregulation in diffuse large B-cell lymphoma. Semin Cancer Biol. 39:26–31. 2016. View Article : Google Scholar : PubMed/NCBI

38 

Yang G, Zhou Y, Liu X, Xu L, Cao Y, Manning RJ, Patterson CJ, Buhrlage SJ, Gray N, Tai YT, et al: A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia. Blood. 122:1222–1232. 2013. View Article : Google Scholar : PubMed/NCBI

39 

Kelly PN, Romero DL, Yang Y, Shaffer AL III, Chaudhary D, Robinson S, Miao W, Rui L, Westlin WF, Kapeller R and Staudt LM: Selective interleukin-1 receptor-associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy. J Exp Med. 212:2189–2201. 2015. View Article : Google Scholar : PubMed/NCBI

40 

Markovtsov VV, Lamagna C, Chan M, Yi S, Young C, Frances R, Siu S, Braselmann S, Li H, Singh R, et al: Potential role for R191, potent and selective IRAK4 kinase inhibitor, in treatment of hematologic malignancies. AACR Abstract. 2016.

41 

Ni H, Shirazi F, Baladandayuthapani V, Lin H, Kuiatse I, Wang H, Jones RJ, Berkova Z, Hitoshi Y, Ansell SM, et al: Targeting myddosome signaling in Waldenström's macroglobulinemia with the interleukin-1 receptor-associated kinase 1/4 inhibitor R191. Clin Cancer Res. 24:6408–6420. 2018. View Article : Google Scholar : PubMed/NCBI

42 

Treon SP, Xu L, Yang G, Zhou Y, Liu X, Cao Y, Sheehy P, Manning RJ, Patterson CJ, Tripsas C, et al: MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. N Engl J Med. 367:826–833. 2012. View Article : Google Scholar : PubMed/NCBI

43 

Liu X, Hunter ZR, Xu L, Chen J, Chen JG, Tsakmaklis N, Patterson CJ, Castillo JJ, Buhrlage S, Gray N, et al: Targeting myddosome assembly in Waldenström macroglobulinaemia. Br J Haematol. 177:808–813. 2017. View Article : Google Scholar : PubMed/NCBI

44 

Kim Y, Ju H, Kim DH, Yoo HY, Kim SJ, Kim WS and Ko YH: CD79B and MYD88 mutations in diffuse large B-cell lymphoma. Hum Pathol. 45:556–564. 2014. View Article : Google Scholar : PubMed/NCBI

45 

Yamada S, Ishida Y, Matsuno A and Yamazaki K: Primary diffuse large B-cell lymphomas of central nervous system exhibit remarkably high prevalence of oncogenic MYD88 and CD79B mutations. Leuk Lymphoma. 56:2141–2145. 2015. View Article : Google Scholar : PubMed/NCBI

46 

Wang JQ, Jeelall YS, Humburg P, Batchelor EL, Kaya SM, Yoo HM, Goodnow CC and Horikawa K: Synergistic cooperation and crosstalk between MYD88L265P and mutations that dysregulate CD79B and surface IgM. J Exp Med. 214:2759–2776. 2017. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

November 2019
Volume 42 Issue 5

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Wang, X., Tan, Y., Huang, Z., Huang, N., Gao, M., Zhou, F. ... Feng, W. (2019). Disrupting myddosome assembly in diffuse large B‑cell lymphoma cells using the MYD88 dimerization inhibitor ST2825. Oncology Reports, 42, 1755-1766. https://doi.org/10.3892/or.2019.7282
MLA
Wang, X., Tan, Y., Huang, Z., Huang, N., Gao, M., Zhou, F., Hu, J., Feng, W."Disrupting myddosome assembly in diffuse large B‑cell lymphoma cells using the MYD88 dimerization inhibitor ST2825". Oncology Reports 42.5 (2019): 1755-1766.
Chicago
Wang, X., Tan, Y., Huang, Z., Huang, N., Gao, M., Zhou, F., Hu, J., Feng, W."Disrupting myddosome assembly in diffuse large B‑cell lymphoma cells using the MYD88 dimerization inhibitor ST2825". Oncology Reports 42, no. 5 (2019): 1755-1766. https://doi.org/10.3892/or.2019.7282